Abstract:Lysine malonylation, a novel identified protein posttranslational modification (PTM), is conservative and present in both eukaryotic and prokaryotic cells. Previous studies have reported that malonylation plays an important role in inflammation, angiogenesis, and diabetes. However, its potential role in cardiac remodeling remains unknown. Here, we observed a reduced lysine malonylation in hypertrophic mice hearts created by transverse aortic constriction (TAC) for 8 weeks. We also detected a decreased lysine malonylation in hypertrophic H9C2 cardiomyocytes induced by angiotensin II for 48 h. Using a proteomic method based on affinity purification and LC-MS/MS, we identified total 679 malonylated sites in 330 proteins in the hearts of sham mice and TAC mice. Bioinformatic analysis of the proteomic data revealed enrichment of malonylated proteins involved in cardiac structure and contraction, cGMP-PKG pathway, and metabolism. Specifically, we detected a decreased lysine malonylation in myocardial isocitrate dehydrogenase 2 (IDH2) by immunoprecipitation coupled with Western blotting both in vivo and in vitro. Together, our work suggests an important role and implication of protein lysine malonylation in cardiac hypertrophy, especially the IDH2.SignificanceHeart failure is the terminal stage of cardiac hypertrophy, which imposes an enormous clinical and economic burden worldwide. Despite our knowledge on the pathophysiology of the disease, current therapeutic approaches are still largely limited. Cardiac hypertrophy can be regulated at post-translational modifications (PTMs), and several PTMs have been reported in cardiac hypertrrophy and heart failure. In our study, we first reported a novel PTMs, lysine malonylation, in cardiac hypertophy. we found a reduced lysine malonylation in hypertrophic mice hearts in vivo and H9C2 cardiomyocytes after stimulating with angiotensinII for 48 h in vitro. Using affinity purification and LC-MS/MS, we identified 679 malonylated sites in 330 proteins in the hearts of sham and TAC mice. Compared to the sham group, 5 sites in 2 proteins were quantified as downregulated targets using a 2-fold threshold (downregulation <0.5-fold, P < 0.05). Functional analysis showed a significant enrichment in cardiac structure and contraction, cGMP-PKG pathway and metabolism. Notably, we identified a decreased Kmal level in isocitrate dehydrogenase 2 (IDH2), but the protein level of IDH2 has no changed in cardiac hypertrophy, These results highlight that lysine malonylation is associated with cardiac hypertrophy, and may be a new therapeutic target of the disease.

Lactate regulates pathological cardiac hypertrophy via histone lactylation modification

Lactate Dehydrogenase A Governs Cardiac Hypertrophic Growth in Response to Hemodynamic Stress

Abnormalities in lysine degradation are involved in early cardiomyocyte hypertrophy development in pressure-overloaded rats

Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis

α-myosin heavy chain lactylation maintains sarcomeric structure and function and alleviates the development of heart failure

Global profiling of protein lysine malonylation in mouse cardiac hypertrophy

Long noncoding RNA AK144717 exacerbates pathological cardiac hypertrophy through modulating the cellular distribution of HMGB1 and subsequent DNA damage response

Lactate promotes myogenesis via activating H3K9 lactylation-dependent up-regulation of Neu2 expression

Recent discoveries of the role of histone modifications and related inhibitors in pathological cardiac hypertrophy

Fibroblast-to-cardiomyocyte Lactate Shuttle Modulates Hypertensive Cardiac Remodelling.

Low density lipoprotein receptor-related protein 1 regulates cardiac hypertrophy induced by pressure overload

New mechanisms: From lactate to lactylation to rescue heart failure

lncExACT1 and DCHS2 Regulate Physiological and Pathological Cardiac Growth

Identification of a long noncoding RNA Gm17501 as a novel negative regulator of cardiac hypertrophy

LITAF acts as a novel regulator for pathological cardiac hypertrophy

The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure

Metabolic Substrates, Histone Modifications, and Heart Failure.

The function of LncRNA-H19 in cardiac hypertrophy

Isoprenaline Inhibits Histone Demethylase LSD1 to Induce Cardiac Hypertrophy

Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors

Lactate dehydrogenase A (LDHA)-mediated lactate generation promotes pulmonary vascular remodeling in pulmonary hypertension